(S)-Sunvozertinib (Synonyms: (S)-DZD9008) |
| Catalog No.GC63797 |
Le (S)-Sunvozertinib ((S)-DZD9008), l'énantiomère S du Sunvozertinib, présente une activité inhibitrice contre les insertions EGFR exon 20 NPH et ASV, la mutation EGFR L858R/T790M et l'insertion Her2 exon20 YVMA (IC50 = 51,2 nM, 51,9 nM , 1 nM et 21,2 nM, respectivement). Le (S)-Sunvozertinib inhibe également la BTK.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2370013-49-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK[1].
(S)-Sunvozertinib shows proliferation inhibition of Ba/F3 EGFR NPH ins (GI50=139.7 nM), Ba/F3 FGFR ASV ins (155.7 nM), NCI-HI975 EGFRL858R/T790M (24.4), Her2 YVMA ins (827 nM) and WT EGFR (84.8 nM)[1].(S)-Sunvozertinib shows proliferation inhibition of BTK WT cells (OCI-LY-10, TMD-8, Ri-1and DB, with GI50 ranging from 13.7-48 nM)[1].
[1]. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *